Evidence Table 104. KQ 3—Continuous Glycosylated hemoglobin (HbA1c)

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **CVD Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome/ Unit of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Manuel200442Parallel | At high risk for CHD | Atorvastatin | 20 | Vitamin E | 11 | Fasting, measured using a HPLC cation exchange columnUnit: measured as percentage | NR | P: NS | P: NS | N/A | Medium |
| Placebo | 11 | NR | P: NS |
| Playford200358Parallel | At high risk for CHD | Fenofibrate | 200 | Co-Q10 + Fenofibrate | 18 | Measured after 14 hr fast;Unit: measured as percentage | Mean: 7.2SE:0.2 | Mean:-0.3 | Mean:0.2P:0.032Crude difference in means: 0.2P:0.832 | N/A | Low-medium |
| No Treatment | 17 | Mean:7.4SE:0.4 | Mean:0.3 |
| Co-Q10 | 20 | Mean: 7.0SE:0.3 | Mean:0.1 |
| Placebo | 18 | Mean:6.6SE:0.2 | Mean:0.3 |
| Bays20106Parallel | Unclear | Atorvastatin | 10-40 | Omega-3 | 122 | NRUnit: measured as percentage | NR | Mean: 0.18SD: 0.45 | NR | N/A | Medium |
| Placebo | 121 | NR | Mean: 0.10SD: 0.33 |